Could This Federal Bill Create a Pharmaceutical Path for Full-Spectrum Cannabis?

A newly introduced federal bill could give certain plant-based cannabis medicines 12 years of protection from generic and other follow-on competition, potentially improving the economics of developing complex formulations through the Food and Drug Administration.

The Advancing Botanical Drug Development Act of 2026, or H.R. 10150, was introduced Aug. 27 by Rep. Lauren Boebert, R-Colo., with Rep. Derrick Van Orden, R-Wis., as a cosponsor. The bill was referred to the House Energy and Commerce Committee and has not advanced beyond that stage.

Cannabis is never mentioned in the three-page legislation. Its potential relevance comes from how the FDA regulates medicines made from plants.

The FDA defines botanical drugs as products made from plant materials, algae, or fungi and intended to diagnose, treat, mitigate, cure, or prevent disease. Unlike supplements or products sold through state cannabis markets, botanical drugs must complete the federal drug-approval process and demonstrate safety, efficacy, and manufacturing consistency.

Under H.R. 10150, a qualifying botanical drug approved through a full new drug application could receive a 12-year period during which the FDA could not make certain competing applications effective. The provision would apply to full applications submitted after the bill became law.

The restriction would cover abbreviated new drug applications filed under Section 505(j), the pathway generally used by generic drugs, and 505(b)(2) applications that rely partly on findings or data associated with an already approved product.

The legislation would not prohibit every company from developing a competing treatment. Its text does not block a sponsor from pursuing an independently supported full new drug application that does not reference or rely on the protected drug.

Where Cannabis Could Fit

The FDA expressly directs researchers developing cannabis-derived medicines to its botanical-drug guidance and encourages them to consult the agency’s Botanical Review Team. That creates a potential pathway for cannabis formulations containing multiple plant constituents to qualify if they meet the eventual statutory and regulatory definition.

But the bill would not automatically cover every cannabinoid medicine.

Products containing highly purified substances are generally excluded from the FDA’s botanical-drug category. That could leave medicines based on isolated or highly purified cannabinoids outside the proposed exclusivity provision.

The distinction is visible in the FDA’s existing cannabis approvals. The agency has approved one cannabis-derived medicine, Epidiolex, which contains purified cannabidiol. It has also approved three synthetic cannabis-related drugs: Marinol, Syndros and Cesamet. None establishes that a complex, whole-plant cannabis formulation would receive the protection contemplated by H.R. 10150.

Eligibility would ultimately depend on the product, its composition, and regulations issued by the Department of Health and Human Services. The bill defines a botanical drug as one determined by the HHS secretary through regulation, leaving an important part of the framework unresolved.

A Longer Runway for Drug Developers

The commercial argument behind the proposal is that botanical medicines can be difficult to standardize and protect through conventional patents.

Plants can vary by genetics, growing conditions, harvesting practices, and processing methods. Developers must establish controls over raw materials while demonstrating that different production batches deliver consistent quality and therapeutic effects.

The FDA says therapeutic consistency may require a combination of agricultural controls, chemical testing, validated manufacturing processes, biological assays, and clinical data. Congress identified those requirements as potential sources of additional cost and commercial uncertainty.

“Botanical drugs are FDA-approved medicines, not dietary supplements,” Boebert said in her announcement of the legislation. She said the proposal would create greater certainty for developers without eliminating clinical trials or reducing FDA safety and effectiveness requirements.

Only four botanical products have received FDA approval through new drug application or biologics pathways, according to the agency.

For cannabis businesses, the bill’s immediate effect is limited. It would not change federal cannabis laws, approve any product, or protect conventional flower, extracts, edibles, or other state-licensed products.

Its significance lies further upstream. If enacted, the 12-year window could make FDA development more attractive for pharmaceutical companies pursuing standardized, multi-constituent cannabis medicines. It could also delay generic and follow-on competition for products that successfully reach the market—giving the original developer more time to recover clinical, manufacturing, and regulatory investments.

A New Pharmaceutical Channel for Cannabis?

H.R. 10150 could help establish a pharmaceutical channel for cannabis products that currently fit poorly within the FDA system.

That channel would not cover conventional flower, dispensary extracts, edibles, or products marketed through state medical cannabis programs. The likely candidates would be standardized, multi-constituent formulations developed for specific medical indications and supported by clinical trials and a full new drug application.

The distinction is important because FDA’s existing cannabis approvals center on purified or synthetic cannabinoids. Epidiolex contains purified CBD, while Marinol, Syndros and Cesamet use synthetic cannabis-related compounds. Those products resemble conventional pharmaceuticals because developers can identify, measure, and reproduce one principal active ingredient.

Full-spectrum cannabis products present a different problem. They may contain numerous cannabinoids, terpenes, flavonoids, and other compounds in varying concentrations. Developers may believe that the therapeutic effect depends on the interaction among several constituents, but that proposition creates scientific and commercial complications.

A company must determine which constituents matter, how much variation is acceptable, and whether every manufactured batch produces a sufficiently consistent therapeutic effect. Genetics, cultivation conditions, harvest timing, storage, and extraction can all change the chemical profile. Even when two batches contain the same amount of THC or CBD, differences in their secondary constituents could make them materially different pharmaceutical products.

Developers must therefore control not only the finished medicine but also the plant material and production system behind it. That can require tightly controlled cultivars, documented agricultural practices, standardized extraction, chemical fingerprinting, biological assays and clinical comparisons across multiple batches.

This makes full-spectrum drug development expensive and difficult. It also creates an intellectual-property problem: naturally occurring compounds and plant combinations can be harder to protect through conventional patents than newly invented molecules.

Why a Broad Botanical Category Matters

The botanical-drug category offers a way to regulate complex cannabis medicines without forcing developers to identify a single compound responsible for the entire therapeutic effect.

FDA’s framework allows the agency to evaluate a botanical medicine through the totality of the evidence. Instead of relying exclusively on one isolated active ingredient, a developer can use raw-material controls, chemical fingerprints, manufacturing standards, biological assays and clinical data to demonstrate that a complex formulation remains consistent, safe and effective.

That broader approach could be particularly important for cannabis. If FDA required every cannabis medicine to be reduced to purified CBD, THC or another isolated cannabinoid, formulations whose claimed value comes from multiple plant constituents would have no practical pharmaceutical pathway.

H.R. 10150 could make that pathway commercially viable. Its proposed 12-year exclusivity period would prevent the FDA from making effective generic applications and certain follow-on applications that rely on the protected botanical drug. A competitor could still conduct its own development program and seek approval through a full new drug application, but reproducing the clinical and manufacturing work behind a complex botanical medicine could be costly.

The legislation would effectively convert some of the difficulties associated with full-spectrum cannabis into a competitive barrier.

The same complexity that makes the product hard to standardize, patent, and approve would also make it difficult for competitors to copy once approved.

That would primarily benefit pharmaceutical developers, clinical research companies, specialized extraction businesses, and cultivators capable of producing pharmaceutical-grade plant material. Existing cannabis operators would not automatically gain access to the channel. They would need to build an FDA-compliant development operation or partner with companies that understand clinical trials, pharmaceutical manufacturing, and federal drug applications.

Europe provides evidence that such a model is technically possible. European rules recognize herbal medicinal products containing complex plant preparations and allow them to be evaluated through traditional-use, well-established-use, or full marketing-authorization pathways. Regardless of the route, companies must provide a complete quality dossier and comply with pharmaceutical manufacturing and pharmacovigilance requirements.

The United States does not currently offer botanical drugs a comparable specialized incentive. By providing 12 years of protection, H.R. 10150 would go further, using exclusivity to attract investment into medicines that may be scientifically promising but commercially difficult to develop.

Cannabis is not named in the legislation, and there is no direct evidence that its sponsors designed the bill specifically for cannabinoids. Nevertheless, standardized, multi-constituent cannabis medicines closely match the development problems identified in the bill: variable plant materials, difficult batch consistency, multiple active constituents, and inadequate conventional intellectual-property protection.

For cannabis drug developers, the bill could create something that has largely been missing from the federal framework: a protected route for developing the plant as a complex medicine rather than treating it only as a source of isolated pharmaceutical compounds.